文献速递妇科

卵巢透明细胞癌全外显子组测序的基因组图谱

Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing.
PubMed 文献 · Gynecol Oncol · 2017-12-09

该研究对15例韩国卵巢透明细胞癌(OCCC)患者的新鲜冷冻肿瘤组织及匹配血清进行全外显子组测序,其中子宫内膜异位症相关OCCC 5例、非相关OCCC 10例。OCCC呈现复杂基因组改变,PIK3CA和ARID1A突变率均为40%,KRAS突变率20%,增殖与生存相关通路改变占87%。EMS-OCCC与非EMS-OCCC组间遗传改变频率无显著差异。

要点

  • 15例韩国OCCC中,PIK3CA和ARID1A突变率各为40%,KRAS突变率为20%。
  • 拷贝数获得常见于GNAS(47%)、MYC(40%)和NTRK1(33%)。
  • EMS-OCCC与非EMS-OCCC组间遗传改变频率无显著差异。

核心结论

  • 研究成功描绘了15例韩国OCCC患者的基因组图谱,并识别出该恶性肿瘤的潜在治疗靶点。

研究设计与样本

  • 研究纳入2012年至2016年间在首尔大学医院人类生物样本库采集的15例OCCC患者样本,其中病理确诊EMS-OCCC 5例、Non-EMS-OCCC 10例。
  • 对15份新鲜冷冻OCCC组织及匹配血清样本进行下一代测序全外显子组测序。

主要发现

  • 每例肿瘤样本外显子突变数中位数为178(范围111-25,798),体细胞拷贝数变异数中位数为343(范围43-1,820)。
  • 15例韩国OCCC中14个基因共发现54个体细胞突变,包括PIK3CA(40%)、ARID1A(40%)和KRAS(20%)。
  • 拷贝数获得常见于GNAS(47%)、MYC(40%)和NTRK1(33%);拷贝数丢失常见于TET2(73%)、TSC1(67%)、BRCA2(60%)和SMAD4(47%)。
  • 87%的OCCC存在增殖与生存相关通路(包括PI3K/AKT、TP53和ERBB2通路)显著改变,47%的OCCC存在染色质重塑相关改变。
  • EMS-OCCC与Non-EMS-OCCC组间遗传改变频率未检测到显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To analyze whole exome sequencing (WES) data on ovarian clear cell carcinoma (OCCC) in Korean patients via the technique of next generation sequencing (NGS). Genomic profiles were compared between endometriosis-associated OCCC (EMS-OCCC) and Non-EMS-OCCC. METHODS: We used serum samples and cancer tissues, stored at the Seoul National University Hospital Human Biobank, that were initially collected from women diagnosed with OCCC between 2012 and 2016. In total, 15 patients were enrolled: 5 with pathologically confirmed EMS-OCCC and 10 with Non-EMS-OCCC. We performed NGS WES on 15 fresh frozen OCCC tissues and matched serum samples, enabling comprehensive genomic characterization of OCCC. RESULTS: OCCC was characterized by complex genomic alterations, with a median of 178 exonic mutations (range, 111-25,798) and a median of 343 somatic copy number variations (range, 43-1,820) per tumor sample. In all, 54 somatic mutations were discovered across 14 genes, including PIK3CA (40%), ARID1A (40%), and KRAS (20%) in the 15 Korean OCCCs. Copy number gains in NTRK1 (33%), MYC (40%), and GNAS (47%) and copy number losses in TET2 (73%), TSC1 (67%), BRCA2 (60%), and SMAD4 (47%) were frequent. The significantly altered pathways were associated with proliferation and survival (including the PI3K/AKT, TP53, and ERBB2 pathways) in 87% of OCCCs and with chromatin remodeling in 47% of OCCCs. No significant differences in frequencies of genetic alterations were detected between EMS-OCCC and Non-EMS-OCCC groups. CONCLUSION: We successfully characterized the genomic landscape of 15 Korean patients with OCCC. We identified potential therapeutic targets for the treatment of this malignancy.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Kim SI, Lee JW, Lee M, et al. Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing. Gynecol Oncol. 2017. PMID: 29233531. doi:10.1016/j.ygyno.2017.12.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。